Standout Papers

Risdiplam in Type 1 Spinal Muscular Atrophy 2021 2026 2022 2024248
  1. Risdiplam in Type 1 Spinal Muscular Atrophy (2021)
    Giovanni Baranello, Basil T. Darras et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 59 standout
Sub-graph 1 of 24

Citing Papers

Past, present, and future of CRISPR genome editing technologies
2024 Standout
CRISPR technologies for genome, epigenome and transcriptome editing
2024 Standout
1 intermediate paper

Works of Andrea Klein being referenced

Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland
2022
Risdiplam in Type 1 Spinal Muscular Atrophy
2021 Standout

Author Peers

Author Last Decade Papers Cites
Andrea Klein 815 492 289 68 1.4k
En Kimura 1082 282 199 85 1.6k
Simon H. Parson 980 759 385 57 1.9k
Anna Kostera‐Pruszczyk 578 399 258 110 1.3k
Edmar Zanoteli 900 560 396 149 1.7k
Francesca Magri 1223 418 131 73 1.7k
J. F. Pellissier 998 366 221 90 2.1k
Teresa Gidaro 899 405 274 63 1.2k
M Reznik 449 357 295 77 1.5k
Daisuke Taura 956 194 400 55 2.1k
M. Mayer 1032 329 198 49 1.5k

All Works

Loading papers...

Rankless by CCL
2026